How to Verify Cannabis Abstinence in PTSD With Cannabis Use Disorder
How can clinicians classify sustained cannabis abstinence over 12 weeks in patients with PTSD and cannabis use disorder using self-report and urine testing?
When a patient with PTSD and cannabis use disorder is attempting to stop cannabis, self-report alone may be insufficient to distinguish sustained abstinence from intermittent use. This guide summarizes the study's practical abstinence classification method, which combined Timeline Followback reporting with semi-quantitative urine THC-COOH testing.
-
Collect baseline self-report and urine toxicology
Start with a baseline assessment of cannabis use using self-report and urine testing before follow-up begins. In the study, abstinence was assessed with the Timeline Followback and semi-quantitative urine carboxy-THC analysis at baseline.
-
Use Timeline Followback to determine any interval cannabis use
At follow-up, ask about cannabis use using Timeline Followback and reduce the result to a binary abstinence variable of yes or no. The investigators did not use quantitative TLFB consumption data because of heterogeneous administration methods and potency, and instead used TLFB to determine whether any use occurred.
-
Verify abstinence with urine THC-COOH testing
Confirm self-reported abstinence with semi-quantitative urine THC-COOH assays. The study used a NarcoCheck test with detection levels of 0, 18, 50, 150, 300, and 600 ng/mL and selected 50 ng/mL as the abstinence cutoff based on prior literature to distinguish residual excretion from new use under supervised abstinence.
-
Test at prespecified follow-up timepoints
Obtain urine testing repeatedly across the abstinence attempt rather than relying on a single end-point sample. In the study, testing occurred at weeks 1, 2, 3, 4, 8, and 12, while formal abstinence classification depended on the week 4, week 8, and week 12 results.
-
Classify continuous abstinence using both criteria
Classify a patient as continuously abstinent only if they report no cannabis use between baseline and week 12 and have urine THC-COOH levels of 50 ng/mL or lower at weeks 4, 8, and 12. This combined rule was the study's definition of 12-week biochemically verified abstinence.
-
Classify all other patterns as nonabstinence
If the patient reports cannabis use at any point or has THC-COOH greater than 50 ng/mL at week 4, 8, or 12, classify them as nonabstinent. This category included continued use and intermittent abstinence in the study.
Clinical Considerations
- The study's abstinence classification was binary and could not capture gradual reduction in cannabis use among nonabstainers.
- Self-reported cannabis use may still introduce recall, response, or social desirability bias even when combined with urine verification.
- The 8-week and 12-week follow-up assessments used a yes/no abstinence question alongside biochemical verification, limiting nuance in later follow-up data.
- This verification approach was used in a research setting with repeated testing and may be harder to replicate in routine practice.
Bottom Line
To classify sustained abstinence in this comorbid PTSD and CUD population, combine no self-reported cannabis use with urine THC-COOH levels of 50 ng/mL or lower at weeks 4, 8, and 12.
